Nanobiotix ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY Revenue (est.)
$44.7Mnext fiscal year
FY EPS (est.)
-$0.15next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly42.1MTarget: Sufficient to fund operations into 2029
CONVERGE Phase 2 NSCLC Objective Response Rate (ORR) Annually85.7%Target: Maintain high efficacy in expanded randomized cohorts
NANORAY-312 Phase 3 Head and Neck Cancer Trial Progress Quarterly335.0Target: Reach 335 events for final analysis under amended protocol
Watch Items
- NANORAY-312 Phase 3 Final AnalysisTrigger: Reaching 335 events under the amended protocolAction: Evaluate overall survival (OS) and progression-free survival (PFS) efficacy data to support regulatory filings.
- J&J Partnership Milestone PaymentsTrigger: Achievement of specified development and regulatory goals in head and neck and lung programsAction: Monitor cash inflows of up to $200 million in near-term milestones.
- Curadigm Nanoprimer Platform DevelopmentTrigger: Transition from preclinical in vivo models to clinical IND-enabling studiesAction: Assess systemic bioavailability and hepatic toxicity data to secure external pharma collaborations.
Research as of 19 Jun 2026